Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
News|Articles|November 1, 2019
Sterling Pharma Solutions Invests into US Expansion
Author(s)Pharmaceutical Technology Editors
Contract development and manufacturing organization (CDMO), Sterling Pharma Solutions, has revealed its investment of $1.5 million into a phased expansion of its facility based in North Carolina, United States.
Advertisement
Contract development and manufacturing organization (CDMO), Sterling Pharma Solutions, has revealed its investment of $1.5 million into a phased expansion of its facility based in North Carolina, United States.
As reported in an Oct. 28, 2019 press release, the company’s latest investment follows from its acquisition of US CiVentiChem earlier in the year and forms part of the company’s ongoing growth strategy. The investment will be used to expand the cGMP production suites, add non-GMP scale-up production facility, expand the quality control laboratory, and increase the site’s R&D capacity.
“The North American market now makes up 70% of our customer portfolio.And, having expanded our US presence earlier this year with the acquisition of our facility in North Carolina, we have continued to experience strong growth,” said Mat Minardi, president US Operations in the press release. “This investment will allow us to continue to meet customer expectations and take on new projects, as well as bolster Sterling’s chemistry development capabilities. The specialist capabilities provided by Sterling, particularly our ability to handle challenging chemistries, are in high demand as a result of the increasing complexity of products entering the drug pipeline and the need for more efficient and cost-effective production of APIs. We’re confident this investment will be of huge benefit to our customers.”
Sterling Pharma Solutions will be exhibiting at CPhI WW in Frankfurt from Nov. 5–7, 2019 in Hall 10.1, Stand 101A60
Source:
Advertisement
Related to this article
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Advertisement
Advertisement